Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 11, 2014, Pages 7610-7621

  Behr, Daniel S ^a   Peitsch, Wiebke K ^a   Hametner, Christian ^b   Lasitschka, Felix ^b   Houben, Roland ^c   Schönhaar, Kathrin ^a   Michel, Julia ^a   Dollt, Claudia ^a   Goebeler, Matthias ^c   Marx, Alexander ^a   Goerdt, Sergij ^a   Schmieder, Astrid ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Immune cell infiltration; Merkel cell carcinoma; PD L1; Tertiary lymphoid structures

Indexed keywords

BIOLOGICAL MARKER; CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

AGED; FEMALE; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SKIN TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD274; BIOMARKERS; CARCINOMA, MERKEL CELL; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MERKEL CELL POLYOMAVIRUS; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84919480575     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Schrama D and Becker JC. Merkel cell carcinoma--pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 2011; 25: 1121-1129.
2. Feng H, Shuda M, Chang Y and Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319: 1096-1100.
3. Becker JC, Kauczok CS, Ugurel S, Eib S, Brocker EB and Houben R. Merkel cell carcinoma: molecular pathogenesis, clinical features and therapy. J Dtsch Dermatol Ges 2008; 6: 709-719.
4. Amber K, McLeod MP and Nouri K. The Merkel cell polyomavirus and its involvement in Merkel cell carcinoma. Dermatol Surg 2013; 39: 232-238.
5. Pipas JM. Common and unique features of T antigens encoded by the polyomavirus group. J Virol 1992; 66: 3979-3985.
6. Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, Moore PS and Becker JC. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 2010; 84: 7064-7072.
7. Shuda M, Kwun HJ, Feng H, Chang Y and Moore PS. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Clin Invest 2011; 121: 3623-3634.
8. Rodig SJ, Cheng J, Wardzala J, DoRosario A, Scanlon JJ, Laga AC, Martinez-Fernandez A, Barletta JA, Bellizzi AM, Sadasivam S, Holloway DT, Cooper DJ, Kupper TS, Wang LC and De- Caprio JA. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest 2012; 122: 4645-4653.
9. Touze A, Le Bidre E, Laude H, Fleury MJ, Cazal R, Arnold F, Carlotti A, Maubec E, Aubin F, Avril MF, Rozenberg F, Tognon M, Maruani A, Gu- yetant S, Lorette G and Coursaget P. High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome. J Clin Oncol 2011; 29: 1612-1619.
10. Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, Schrama D, Simonson WT, Lemos BD, Byrd DR, Koelle DM, Galloway DA, Leonard JH, Madeleine MM, Argenyi ZB, Disis ML, Becker JC, Cleary MA and Nghiem P. Tr- anscriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011; 29: 1539-1546.
11. Sihto H, Bohling T, Kavola H, Koljonen V, Salmi M, Jalkanen S and Joensuu H. Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study. Clin Ca- ncer Res 2012; 18: 2872-2881.
12. Shen M, Hu P, Donskov F, Wang G, Liu Q and Du J. Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS One 2014; 9: e98259.
13. Sevko A and Umansky V. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer 2013; 4: 3-11.
14. Pimenta EM and Barnes BJ. Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Im- munity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers. Cancers (Basel) 2014; 6: 969-997.
15. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, Lebecque S, Fri- dman WH and Cadranel J. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26: 4410-4417.
16. de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Alifano M, Cremer I, Fridman WH, Sautes-Fridman C and Dieu-Nosjean MC. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res 2011; 71: 6391-6399.
17. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010; 185: 4977-4982.
18. Silina K, Rulle U, Kalnina Z and Line A. Mani- pulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue? Cancer Immunol Immu- nother 2014; 63: 643-62
19. Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, Lepelley A, Becht E, Katsahian S, Bizouard G, Validire P, Damotte D, Alifano M, Magdeleinat P, Cremer I, Teillaud JL, Fridman WH, Sautes-Fridman C and Dieu-Nosjean MC. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 2014; 189: 832-844.
20. Goc J, Fridman WH, Sautes-Fridman C and Dieu-Nosjean MC. Characteristics of tertiary lymphoid structures in primary cancers. Onco- immunology 2013; 2: e26836.
21. Ott PA, Hodi FS and Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19: 5300-5309.
22. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM and Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
23. Afanasiev OK, Yelistratova L, Miller N, Nagase K, Paulson K, Iyer JG, Ibrani D, Koelle DM and Nghiem P. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res 2013; 19: 5351-5360.
24. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D, Anders RA, Topalian SL and Tau- be JM. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013; 1: 54-63.
25. American Joint Committee on Cancer: AJCC cancer staging handbook. New York: Springer; 2010.
26. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL and Chen L. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra137.
27. Helmbold P, Lahtz C, Enk A, Herrmann-Trost P, Marsch W, Kutzner H and Dammann RH. Frequent occurrence of RASSF1A promoter hypermethylation and Merkel cell polyomavirus in Merkel cell carcinoma. Mol Carcinog 2009; 48: 903-909.
28. Vlahova L, Doerflinger Y, Houben R, Becker JC, Schrama D, Weiss C, Goebeler M, Helmbold P, Goerdt S and Peitsch WK. P-cadherin expression in Merkel cell carcinomas is associated with prolonged recurrence-free survival. Br J Dermatol 2012; 166: 1043-1052.
29. Johnson ME, Zhu F, Li T, Wu H, Galloway TJ, Farma JM, Perlis CS and Turaka A. Absolute lymphocyte count: A potential prognostic factor for Merkel cell carcinoma. J Am Acad Dermatol 2014; 70: 1028-1035.
30. Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, Flejou JF, Gibault L, Verkarre V, Regnard JF, Pages ON, Oudard S, Mlecnik B, Sautes-Fridman C, Fridman WH and Damotte D. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013; 19: 4079-4091.
31. Cipponi A, Mercier M, Seremet T, Baurain JF, Theate I, van den Oord J, Stas M, Boon T, Coulie PG and van Baren N. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res 2012; 72: 3997-4007.
32. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Am- brosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ and Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538-18543.
33. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Ca- mus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
34. Schumacher K, Haensch W, Roefzaad C and Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61: 3932-3936.
35. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO and Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29: 1949-1955.
36. Coronella-Wood JA and Hersh EM. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 2003; 52: 715-738.
37. Mizukami M, Hanagiri T, Baba T, Fukuyama T, Nagata Y, So T, Ichiki Y, Sugaya M, Yasuda M, Takenoyama M, Sugio K and Yasumoto K. Ide- ntification of tumor associated antigens recognized by IgG from tumor-infiltrating B cells of lung cancer: correlation between Ab titer of the patient's sera and the clinical course. Cancer Sci 2005; 96: 882-888.
38. Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase K, Jing L, Marshak JO, Dong L, Carter J, Lai I, Farrar E, Byrd D, Galloway D, Yee C, Koelle DM and Nghiem P. Merkel cell polyomavirus-specific CD8(+) and CD4(+) T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res 2011; 17: 6671-6680.
39. Bergomas F, Grizzi F, Doni A, Pesce S, Laghi L, Allavena P, Mantovani A and Marchesi F. Ter- tiary intratumor lymphoid tissue in colo-rectal cancer. Cancers (Basel) 2011; 4: 1-10.
40. Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A and Mule JJ. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol 2011; 179: 37-45.
41. Gottlin EB, Bentley RC, Campa MJ, Pisetsky DS, Herndon JE 2nd and Patz EF Jr. The As- sociation of Intratumoral Germinal Centers with early-stage non-small cell lung cancer. J Thorac Oncol 2011; 6: 1687-1690.
42. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothe F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart M, Sotiriou C and Willard-Gallo K. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin In- vest 2013; 123: 2873-2892.
43. Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ou- akrim H, Becht E, Alifano M, Validire P, Remark R, Hammond SA, Cremer I, Damotte D, Fridman WH, Sautes-Fridman C and Dieu-Nosjean MC. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res 2014; 74: 705-715.
44. Brown K, Sacks SH and Wong W. Tertiary lymphoid organs in renal allografts can be associated with donor-specific tolerance rather than rejection. Eur J Immunol 2011; 41: 89-96.
45. Prieto Munoz I, Pardo Masferrer J, Olivera Ve- gas J, Medina Montalvo MS, Jover Diaz R and Perez Casas AM. Merkel cell carcinoma from 2008 to 2012: reaching a new level of understanding. Cancer Treat Rev 2013; 39: 421-429.
46. Bichakjian CK, Lowe L, Lao CD, Sandler HM, Bradford CR, Johnson TM and Wong SL. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer 2007; 110: 1-12.
47. Becker J, Mauch C, Kortmann RD, Keilholz U, Bootz F, Garbe C, Hauschild A and Moll I. Short German guidelines: Merkel cell carcinoma. J Dtsch Dermatol Ges 2008; 6 Suppl 1: S15-16.
48. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, To- palian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Ala- parthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A and Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
49. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hem- minki A, Alvarez RD, Emilie D, Curiel DT, Chen L and Zou W. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562-567.
50. Topalian SL, Drake CG and Pardoll DM. Tar- geting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24: 207-212.